Aurobindo Pharma share price
NSE: AUROPHARMABSE: 524804Pharmaceuticals & BiotechnologyMid Cap
Aurobindo Pharma Limited · Face value ₹1 Face value. The nominal value of one share as the company issued it, the unit its share capital is counted in and a dividend can be stated as a percentage of; it has no link to the share price. Face value in the glossary · Listed Apr 1995 on BSE, Jul 2000 on NSE
Last close ₹1,659.90up ₹15.10 (0.92%)BSE ₹1,655.00
Share price at the NSE close on 29 Oct 2026. Previous close ₹1,644.80.
29 Oct: open ₹1,643.00, high ₹1,659.90, low ₹1,635.10
52-week range of traded prices to 29 Oct 2026
₹1,091.20Low, 30 Oct 2025₹1,740.00High, 24 Sep 2026
- Next results date: the board meets on 4 Nov 2026 to consider: financial results and dividend. The notice · Results calendar
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies. Market capitalisation: how it is worked out
- ₹95,507 Cr138th largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. Price to earnings, trailing: how it is worked out
- 25.73
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. Price to book: how it is worked out
- 2.52
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- Nonein the last 12 months
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business. Net worth is the average of the latest balance sheet and the one a year before it.
- 10.5%
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet.
- 11.5%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Mar 2026.
- 0.20
- Volume, NSEVolume. Shares traded on the last trading day; delivery is the part buyers kept rather than sold again the same day. Volume in the glossary
- 4,10,88155.8% delivered
About Aurobindo Pharma
Aurobindo Pharma Limited, headquartered in Hyderabad, develops, manufactures and sells generic medicines, branded specialty medicines, injectables and active pharmaceutical ingredients (APIs, the chemical substances that make a medicine work).1 It sells to generic drug companies, large pharmaceutical companies, institutional buyers and health care professionals, with the United States and Europe as its largest markets.23
It makes both finished medicines, called formulations, and APIs, which it sells to other companies and also uses in its own formulations.4 Its subsidiary Eugia Pharma Specialities makes specialty medicines such as cancer drugs and complex injectables, and Apitoria Pharma runs the API business.56 CuraTeQ Biologics develops biosimilars (near-copies of biological medicines whose patents have expired).7 TheraNym Biologics is building a large plant to make biological medicines under contract for other drug companies, with MSD as its anchor customer (the main customer the plant is built for).8
It sells in over 150 countries, and most of its manufacturing and packaging facilities are in India, with others in the United States, China, Portugal and Brazil.1 Its workforce numbers over 40,000.1
It was incorporated in 1986.9 Its promoters include K. Nithyananda Reddy, its Vice Chairman and Managing Director, and P. V. Ramprasad Reddy, a non-executive director.1011
Aurobindo Pharma key points
Results
- In the quarter to Jun 2026, consolidated revenue was ₹9,150 crore, up 16.3% from ₹7,868 crore a year earlier, and net profit was ₹1,032 crore against ₹824 crore.12
- In the same quarter, operating EBITDA (earnings before interest, tax, depreciation and amortisation), leaving out a one-time charge of ₹43 crore, was ₹1,924 crore, a margin of 21%.13
- In the year to Mar 2026, consolidated revenue was ₹33,653 crore, up 6.1%, EBITDA was ₹6,856 crore at a 20.4% margin, and net profit was ₹3,503 crore.141516
- At the end of June 2026 it held net cash (cash and investments above its borrowings) of about $42 million, after paying $247 million for buying Lannett and $85 million for a share buyback.17
Market position
Revenue mix
- Revenue by business1819
Item quarter to Jun 2026 quarter to Jun 2025 US ₹3,770 crore ₹3,488 crore Europe ₹2,937 crore ₹2,338 crore Growth Markets (India, Canada, Mexico, Brazil, others) ₹1,063 crore ₹772 crore ARV (HIV medicines) ₹330 crore ₹355 crore APIs ₹1,049 crore ₹916 crore - Share of revenue2021Markets outside India made up 91% of revenue.
Item year to Mar 2026 US 43% Europe 31% APIs 12% Growth Markets 10% ARV 4% - Europe net revenue crossed €1 billion in the year to Mar 2026, made up of €974 million of subsidiary sales and about €40 million billed from India to business customers.22
Plants and capacity
- It has 31 commercial manufacturing facilities, 18 for formulations and 13 for APIs, with formulation capacity of more than 65 billion doses and API capacity of 19,000 metric tonnes (MT).23
- Its penicillin G plant at Kakinada, which cuts its reliance on outside suppliers of starting materials for penicillin-type antibiotics, began production in July 2025.24
- The group's capital spending was ₹3,058 crore (about $340 million) in the year to Mar 2026.25
- Lannett's US plant covers 425k sq ft with capacity of about 3.6 billion doses; on its earnings call of 6 Aug 2026, the company said it ran at about 40% utilisation.2627
Research and development
- The group spent ₹1,590 crore on research and development in the year to Mar 2026, 4.7% of revenue, at 6 centres with a team of more than 1,500 scientists.28
- CuraTeQ sells all 4 of its UK-approved biosimilars in the UK and supplies some of them in France, Germany, Portugal and other European countries.29
- CuraTeQ has filed its denosumab biosimilars Filvizy and Fugevy, for bone loss and for cancer care, with the European Medicines Agency.29
What the company expects
- On its earnings call of 6 Aug 2026, the company said it expects double-digit revenue growth in the year to Mar 2027, with an EBITDA margin above 21%.30
- On its earnings call of 6 Aug 2026, the company said its first US biosimilar filings were imminent and that it aims for at least 3 US biosimilars by 2030.27
- On its earnings call of 6 Aug 2026, the company said its 2 TheraNym contract manufacturing units could bring revenue of about $150 million to $200 million in 2032 in a good case, with EBITDA margins in such business typically 35% to 50%.31
Recent events
- In an exchange filing of 2 Oct 2026, the company said subsidiary Apitoria Pharma had completed buying the A1 Biochem contract research business (research done for other drug companies for a fee); it holds 80% of A1 Biochem Labs (India).32
- On 15 Sep 2026, the company announced that it had received US FDA final approval for beclomethasone dipropionate inhalation aerosol, an asthma medicine and its first metered-dose inhaler.33
- On 29 Jun 2026, its US subsidiary completed buying Lannett Company, which mainly makes controlled substances (medicines restricted by law because they can be misused) such as ADHD treatments, at an enterprise value (price before cash and debt) of $250 million.3426
- On 3 Jun 2026, it inaugurated TheraNym Unit 1; in its presentation of 5 Aug 2026, the company said qualification (checks that the plant meets quality standards) was on track to begin in November 2026.35
Litigation and regulatory matters
- On 14 Aug 2026, the company said Unit I of subsidiary Eugia Pharma Specialities, about 2% of group revenue, had received a US FDA warning letter (a formal notice of breaches of manufacturing rules), with no impact on existing US supplies.36
- On 17 Aug 2026, the company said the US FDA had closed its 2025 inspection of the Raleigh, North Carolina plant as voluntary action indicated (issues found, no regulatory action), so pending inhaler applications from the plant can move through review.37
Last updated
All 37 sources, each with its page
- 1. Annual report, 3 Aug 2026, page 112
- 2. Annual report, 3 Aug 2026, page 115
- 3. Annual report, 3 Aug 2026, page 35
- 4. Annual report, 3 Aug 2026, page 11
- 5. Annual report, 3 Aug 2026, page 12
- 6. Annual report, 3 Aug 2026, page 46
- 7. Annual report, 3 Aug 2026, page 21
- 8. Annual report, 3 Aug 2026, page 14
- 9. Annual report, 3 Aug 2026, page 114
- 10. Annual report, 3 Aug 2026, page 136
- 11. Annual report, 3 Aug 2026, page 90
- 12. Investor presentation, 5 Aug 2026, page 6
- 13. Earnings call, 6 Aug 2026, page 4
- 14. Annual report, 3 Aug 2026, page 112
- 15. Annual report, 3 Aug 2026, page 88
- 16. Annual report, 3 Aug 2026, page 20
- 17. Investor presentation, 5 Aug 2026, page 7
- 18. Investor presentation, 5 Aug 2026, page 9
- 19. Annual report, 3 Aug 2026, page 112
- 20. Annual report, 3 Aug 2026, page 9
- 21. Annual report, 3 Aug 2026, page 49
- 22. Annual report, 3 Aug 2026, page 44
- 23. Annual report, 3 Aug 2026, page 51
- 24. Annual report, 3 Aug 2026, page 52
- 25. Annual report, 3 Aug 2026, page 49
- 26. Annual report, 3 Aug 2026, page 93
- 27. Earnings call, 6 Aug 2026, page 10
- 28. Annual report, 3 Aug 2026, page 89
- 29. Investor presentation, 5 Aug 2026, page 16
- 30. Earnings call, 6 Aug 2026, page 5
- 31. Earnings call, 6 Aug 2026, page 20
- 32. Exchange filing, 2 Oct 2026, page 1
- 33. Exchange filing, 15 Sep 2026, page 2
- 34. Earnings call, 6 Aug 2026, page 9
- 35. Investor presentation, 5 Aug 2026, page 20
- 36. Exchange filing, 14 Aug 2026, page 1
- 37. Exchange filing, 17 Aug 2026, page 1
Results
Consolidated; ₹ crore.Aurobindo Pharma quarterly results
- Revenue growth, 12 monthsRevenue growth, 12 months. The last twelve months against the twelve before them. Left empty where the earlier figure was nought or a loss: growth out of a loss has no percentage.
- +9.1%
- Net profit growth, 12 monthsNet profit growth, 12 months. The last twelve months against the twelve before them. Left empty where the earlier figure was nought or a loss: growth out of a loss has no percentage.
- +9.5%
Quarter to Jun 2026, against the quarter before
- RevenueRevenue. The pill is the change in revenue against the quarter before: this period's figure divided by that one's, less one, in per cent.
- ₹9,150 Crup 3.35%
- Net profitNet profit. The pill is the change in net profit against the quarter before: this period's figure divided by that one's, less one, in per cent. Net profit in the glossary
- ₹1,032 Crup 12.07%
- Net marginNet margin. Net profit as a percentage of revenue: how much of each rupee of sales is left after every cost, interest and tax. Net margin in the glossary
- 11.3%
Revenue by quarter
Peak revenue ₹9,150 Cr, quarter to Jun 2026; lowest ₹7,796 Cr, quarter to Sep 2024
Net profit by quarter, a loss in red
| ₹ crore | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 7,796 | 7,979 | 8,382 | 7,868 | 8,286 | 8,646 | 8,853 | 9,150 |
| Net profit | 817 | 846 | 903 | 824 | 848 | 910 | 921 | 1,032 |
| Net margin | 10.5% | 10.6% | 10.8% | 10.5% | 10.2% | 10.5% | 10.4% | 11.3% |
Consolidated. The last eight quarters. The latest is shaded. Net profit is the whole group's, the other owners of its subsidiaries included; P/E and ROE use the company's own share.
Year to Mar 2026, against the year before
- RevenueRevenue. The pill is the change in revenue against the year before: this period's figure divided by that one's, less one, in per cent.
- ₹33,653 Crup 6.08%
- Net profitNet profit. The pill is the change in net profit against the year before: this period's figure divided by that one's, less one, in per cent.
- ₹3,503 Crup 0.56%
- Net margin
- 10.4%
Revenue by year
Peak revenue ₹33,653 Cr, year to Mar 2026; lowest ₹15,090 Cr, year to Mar 2017
Net profit by year, a loss in red
| ₹ crore | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 15,090 | 16,500 | 19,564 | 23,099 | 24,775 | 23,455 | 24,855 | 29,002 | 31,724 | 33,653 |
| Net profit | 2,302 | 2,423 | 2,365 | 2,830 | 5,334 | 2,647 | 1,928 | 3,169 | 3,484 | 3,503 |
| Net margin | 15.3% | 14.7% | 12.1% | 12.2% | 21.5% | 11.3% | 7.8% | 10.9% | 11.0% | 10.4% |
Consolidated. Years to March. The latest is shaded. Net profit is the whole group's, the other owners of its subsidiaries included; P/E and ROE use the company's own share.
Business segments
In the year to Mar 2026 the company reports one business segment, Pharmaceutical products, which carries all its revenue.
Valuation
Today, against the company's own history.Aurobindo Pharma PE ratio and valuation
Price to earnings
At or below today's level on 93% of 2,479 trading days over the last 10 years.
LowestHighest
Its median18.09Industry median28.38
Price to book
At or below today's level on 69% of 1,974 trading days since Nov 2018.
LowestHighest
Its median2.18Industry median2.99
Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price. When a year's dividend goes ex later than the year before's, the yield reads zero for the days between; a run of under 60 such trading days is left out of the yield's medians and percentiles. The ex-date is the day from which a buyer of the share no longer gets the dividend.
At or below today's level on 7% of 2,479 trading days over the last 10 years.
LowestHighest
Its median0.40%Industry median0.48%
Where the return came from
Yearly rates to Mar 2026, per-share figures restated for splits and bonuses.
| Over | Return a year | Earnings growth | Change in P/E | Dividend yield |
|---|---|---|---|---|
| 1 year | +12.7% | +0.9% | +11.4% | 0.3% |
| 3 years | +36.3% | +22.4% | +11.1% | 0.2% |
| 5 years | +8.7% | −7.9% | +17.4% | 0.5% |
Return is price growth plus the average dividend yield. Change in P/E is (1 + price growth) / (1 + earnings growth) - 1, so the parts compound rather than add. Earnings growth over 5 years includes one-off items (exceptional items and the result of businesses sold or closed) of more than a tenth of the profit of the year to Mar 2021.
Mutual fund holdings
261 funds disclosed a holding for Sep 2026. What they did in Sep 2026, against each fund's month before. 113 of the 149 funds that added or cut are index funds, ETFs or arbitrage funds: an index fund or ETF holds what its index holds, and an arbitrage fund holds the share against a sale of its future. 2 more funds filed their first portfolio on record, holding it.All 261 funds holding Aurobindo Pharma
- Bought for the first timeBought for the first time. Funds that held it at the month's end and had not held it in any month on record before.
- 9
- Bought againBought again. Funds that held it at the month's end, had not held it the month before, and held it in an earlier month.
- 5
- AddedAdded. Funds that held more shares than at the end of the month before.
- 79
- CutCut. Funds that held fewer shares than at the end of the month before.
- 70
- Held unchangedHeld unchanged. Funds that held the same number of shares as at the end of the month before.
- 96
- Sold outSold out. Funds that held it at the end of the month before and hold none at this month's end. Sold out in the glossary
- 7
| Fund | |||
|---|---|---|---|
 HDFC Mid Cap FundHDFC Mutual Fund | 1,33,44,745 | 2.19% | ₹2,231.2 Cr |
 quant ELSS Tax Saver Fundquant Mutual Fund | 66,52,259 | 8.49% | ₹1,112.3 Cr |
| quant Mid Cap Fundquant Mutual Fund | 49,02,846 | 10.71% | ₹819.8 Cr |
 SBI Large & Midcap FundSBI Mutual Fund | 47,00,000 | 1.94% | ₹785.8 Cr |
| quant Multi Cap Fundquant Mutual Fund | 42,57,303 | 9.49% | ₹711.8 Cr |
| SBI Flexicap FundSBI Mutual Fund | 40,07,877 | 3.03% | ₹670.1 Cr |
| SBI Midcap FundSBI Mutual Fund | 30,38,512 | 2.18% | ₹508.0 Cr |
| quant Flexi Cap Fundquant Mutual Fund | 30,04,373 | 6.87% | ₹502.3 Cr |
| HDFC Balanced Advantage FundHDFC Mutual Fund | 27,00,437 | 0.44% | ₹451.5 Cr |
| HDFC Large & Mid Cap FundHDFC Mutual Fund | 21,60,032 | 1.27% | ₹361.2 Cr |
Portfolios disclosed for Sep 2026. Weight is the holding as a share of the fund's assets.
Promoter and insider buying and selling
Trades made since 30 Oct 2025.Aurobindo Pharma insider trading
No promoter, director, key manager or employee bought or sold on the market.
- Promoters and promoter group: no market trade · 12 pledge filings of unclear kind
- Others: no market trade
Bought and sold count trades on the market only. A pledge is shares given to a lender as security for a loan; a lender invokes it by selling them.
Aurobindo Pharma competitors and peers
Pharmaceuticals, 215 listed companies, priced on 29 Oct 2026. The table lists the 8 companies closest to Aurobindo Pharma in market cap.Healthcare companies
Where the company sits among the companies nearest its size
| Company | ||||||||
|---|---|---|---|---|---|---|---|---|
 Zydus LifesciencesZYDUSLIFE | 1,18,144 | 26.18 | 4.36 | +21.1% | −1.3% | 17.7% | 15.9% | 0.08% |
 Dr. Reddy's LaboratoriesDRREDDY | 1,12,264 | 40.10 | 2.89 | −3.5% | −51.5% | 7.5% | 6.0% | 0.59% |
 CiplaCIPLA | 1,09,709 | 37.87 | 3.10 | −0.7% | −46.8% | 8.5% | 9.7% | 0.96% |
 Mankind PharmaMANKIND | 1,01,993 | 45.36 | 5.80 | +13.3% | +28.4% | 13.7% | 13.6% | 0.00% |
 LupinLUPIN | 90,996 | 16.46 | 4.05 | +28.2% | +49.5% | 27.9% | 28.2% | 0.90% |
 Glenmark PharmaceuticalsGLENMARK | 66,012 | 36.72 | 6.28 | +32.9% | +138.4% | 18.6% | 39.8% | 0.11% |
 Alkem LaboratoriesALKEM | 60,727 | 28.15 | 4.39 | +13.4% | −5.6% | 16.7% | 16.5% | 1.04% |
 BioconBIOCON | 57,349 | 115.79 | 1.69 | +9.8% | +28.6% | 1.8% | 2.9% | 0.14% |
Market cap in ₹ crore. Growth is the last twelve months against the twelve before. A figure is left empty where it would rest on a loss or the company has under a year of results on record. ROE is the shareholders' profit over their net worth. ROCE is profit before interest and tax over the whole group's net worth plus borrowings, as in the figures at the top of the page.
Dividends
Per share, by the year it was paid for, and the latest payments.Aurobindo Pharma dividend history
Dividend per share, ₹, restated for later splits and bonuses
Dividend per share. The dividends declared for the year, each restated to today's share count by the splits and bonuses after its own ex-date, added up. Dividend per share in the glossaryHighest ₹9.00 a share, year to Mar 2022.
| Ex-date | Type | Per share |
|---|---|---|
| 8 Aug 2025 | Interim | ₹4.00 |
| 20 Feb 2024 | Interim | ₹1.50 |
| 20 Nov 2023 | Interim | ₹3.00 |
| 17 Feb 2023 | Interim | ₹3.00 |
| 6 Jun 2022 | Interim | ₹4.50 |
| 18 Feb 2022 | Interim | ₹1.50 |
Latest payments, as declared, by ex-date.
Latest announcements
Routine notices left out.Aurobindo Pharma announcements
Oct 2026
2 Oct · General Updates
2 Oct · Business
1 Oct · Business
Aurobindo Pharma share price by year
Each calendar year to 2025.Aurobindo Pharma share price history
| Year | Close at year end | Change | Highest close | Lowest close |
|---|---|---|---|---|
| 2025 | 1,183.00 | −11.4% | 1,353.25 | 1,022.20 |
| 2024 | 1,334.50 | +23.1% | 1,569.40 | 990.40 |
| 2023 | 1,084.00 | +147.3% | 1,092.15 | 404.20 |
| 2022 | 438.30 | −40.3% | 737.30 | 437.15 |
| 2021 | 734.35 | −20.3% | 1,047.95 | 627.60 |
| 2020 | 921.30 | +101.7% | 948.85 | 294.70 |
| 2019 | 456.85 | −37.7% | 831.15 | 395.80 |
| 2018 | 732.95 | +6.5% | 823.55 | 533.35 |
| 2017 | 687.95 | +2.8% | 795.90 | 512.40 |
| 2016 | 669.30 | −23.6% | 881.40 | 588.85 |
₹ per share, adjusted for splits and bonuses since. Change is on the close at the end of the year before.
Recent sessions
The 9 trading days to 28 Oct 2026, as traded on NSE; the latest is at the top of the page.
| Date | Open | High | Low | Close | Average price | Volume | Delivery |
|---|---|---|---|---|---|---|---|
| 28 Oct 2026 | 1,625.00 | 1,650.00 | 1,609.10 | 1,644.80 | 1,638.23 | 5,54,485 | 48.5% |
| 27 Oct 2026 | 1,600.00 | 1,635.00 | 1,597.20 | 1,627.50 | 1,625.93 | 11,64,932 | 60.5% |
| 26 Oct 2026 | 1,562.40 | 1,591.30 | 1,553.00 | 1,590.00 | 1,575.84 | 4,73,129 | 44.1% |
| 23 Oct 2026 | 1,607.70 | 1,608.80 | 1,547.80 | 1,571.70 | 1,566.81 | 6,50,602 | 51.3% |
| 22 Oct 2026 | 1,570.00 | 1,610.90 | 1,547.70 | 1,610.90 | 1,588.78 | 11,15,532 | 63.3% |
| 21 Oct 2026 | 1,621.40 | 1,636.90 | 1,564.00 | 1,578.80 | 1,585.97 | 12,19,785 | 54.6% |
| 19 Oct 2026 | 1,662.10 | 1,681.60 | 1,615.60 | 1,621.40 | 1,646.27 | 7,36,433 | 52.3% |
| 16 Oct 2026 | 1,677.90 | 1,681.70 | 1,655.00 | 1,666.90 | 1,664.91 | 7,96,734 | 52.9% |
| 15 Oct 2026 | 1,653.20 | 1,684.30 | 1,647.10 | 1,677.90 | 1,672.56 | 7,62,099 | 55.6% |
Prices in ₹ per share as traded, not adjusted.
Price adjustments
What the price chart is corrected for, so it reads as one share held throughout.Bonus shares and stock split history
| Ex-date | Event | Price factor | What happened |
|---|---|---|---|
| 20 Jul 2015 | Bonus | 0.5000 | Holders received 1 bonus share for every 1 held. |
| 10 Feb 2011 | Split | 0.2000 | Each share became 5. |
| 8 Oct 2008 | Price move | – | Between two trading sessions the price moved by a fifth or more. No corporate action is on record. Not adjusted for. |
Earlier prices are multiplied by the factor, so the chart reads as one share held throughout. Any other event is noted and not adjusted for.
Company details
- NSE symbol
- AUROPHARMA
- BSE code
- 524804
- ISIN
- INE406A01037
- Industry
- Pharmaceuticals & Biotechnology
- Website
- www.aurobindo.com
- CIN
- L24239TG1986PLC015190
- Corporate identity number, the registrar of companies' code for it
- Incorporated
- 1986
- Registered office
- Plot No.2, Maitrivihar, Ameerpet, Hyderabad 500038, Telangana
- Share registrar
- KFin Technologies Ltd
- Keeps the register of shareholders and handles transfers and dividend payments
In Nifty 200, BSE 200, Nifty 500, BSE 500, Nifty Midcap 150, BSE 150 MidCap Index